Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,305 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kappaB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma.
Terpos E, Heath DJ, Rahemtulla A, Zervas K, Chantry A, Anagnostopoulos A, Pouli A, Katodritou E, Verrou E, Vervessou EC, Dimopoulos MA, Croucher PI. Terpos E, et al. Among authors: dimopoulos ma. Br J Haematol. 2006 Dec;135(5):688-92. doi: 10.1111/j.1365-2141.2006.06356.x. Br J Haematol. 2006. PMID: 17107351 Free article.
Myeloma bone disease and proteasome inhibition therapies.
Terpos E, Sezer O, Croucher P, Dimopoulos MA. Terpos E, et al. Among authors: dimopoulos ma. Blood. 2007 Aug 15;110(4):1098-104. doi: 10.1182/blood-2007-03-067710. Epub 2007 May 9. Blood. 2007. PMID: 17494860 Free article. Review.
Bortezomib in multiple myeloma.
Terpos E, Roussou M, Dimopoulos MA. Terpos E, et al. Among authors: dimopoulos ma. Expert Opin Drug Metab Toxicol. 2008 May;4(5):639-54. doi: 10.1517/17425255.4.5.639. Expert Opin Drug Metab Toxicol. 2008. PMID: 18484921 Review.
Cystatin-C is an independent prognostic factor for survival in multiple myeloma and is reduced by bortezomib administration.
Terpos E, Katodritou E, Tsiftsakis E, Kastritis E, Christoulas D, Pouli A, Michalis E, Verrou E, Anargyrou K, Tsionos K, Dimopoulos MA, Zervas K; Greek Myeloma Study Group. Terpos E, et al. Among authors: dimopoulos ma. Haematologica. 2009 Mar;94(3):372-9. doi: 10.3324/haematol.2008.000638. Haematologica. 2009. PMID: 19252175 Free PMC article. Clinical Trial.
Pathogenesis and management of myeloma bone disease.
Christoulas D, Terpos E, Dimopoulos MA. Christoulas D, et al. Among authors: dimopoulos ma. Expert Rev Hematol. 2009 Aug;2(4):385-98. doi: 10.1586/ehm.09.36. Expert Rev Hematol. 2009. PMID: 21082944 Review.
Current treatment options for myeloma.
Terpos E, Rahemtulla A, Dimopoulos MA. Terpos E, et al. Among authors: dimopoulos ma. Expert Opin Pharmacother. 2005 Jun;6(7):1127-42. doi: 10.1517/14656566.6.7.1127. Expert Opin Pharmacother. 2005. PMID: 15957967 Review.
1,305 results